Business

Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

articleHinova Pharmaceuticals, Inc. Class ANovember 24, 20253/news/announcement-on-voluntary-disclosure-of-obtaining-the-drug-clinical-trial-approval-notice-for-hp518-tablets-an-oral-protac-drug-in-combination-with-anti-tumor-therapy-for-the-treatment-of-advanced-prostate-cancer
Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A